Clin2
NCT07739888Possibly a fitNot yet recruiting

Study of abelacimab for high-risk atrial fibrillation patients

Atrial Fibrillation (AF)

Part of Heart & circulation clinical trials.

This study tests a new medicine called abelacimab for people with atrial fibrillation who cannot take standard blood thinners. The goal is to see if it safely reduces the risk of stroke or blood clots.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
2,500 people
Ages
65 years and older
Study type
Interventional

Who can take part

  • You must have atrial fibrillation and be at high risk for stroke.
  • Your doctor has said you cannot take standard blood thinners.
  • You must have already been taking the study medicine and finished the main part of the study.
  • You must be healthy enough and willing to follow the study rules.
  • You cannot join if you are allergic to the study drug or similar medicines.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05712200Recruiting· Phase 3
Abelacimab for atrial fibrillation when blood thinners aren’t suitable

This Phase 3 study tests whether abelacimab can prevent stroke and other blood-clot problems in people with atrial fibrillation (or atrial flutter) who cannot safely take usual mouth blood thinners. It also looks at safety, especially bleeding risk.

Birmingham, Alabama
NCT07175428Recruiting· Phase 2
Safety of a New Blood Thinner in AFib Patients

This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.

Dothan, Alabama
NCT07085650Recruiting
Atrial Fibrillation Ablation Study

This study is for people with atrial fibrillation who are planning to have a catheter ablation procedure. It will look at how well the heart works after the procedure and how to prevent future events.

Shenyang, Liaoning
NCT07430956Recruiting· Phase 3
Stroke prevention in atrial fibrillation without standard blood thinners

This trial tests a new medication to prevent strokes and blood clots in people with atrial fibrillation (an irregular heartbeat) who cannot safely take standard blood thinners. The drug works by blocking a different clotting factor, which may lower bleeding risks.

Dothan, Alabama
NCT07620262Recruiting
Combined atrial fibrillation treatment and stroke prevention study

This study tests a new approach for people with atrial fibrillation (a type of irregular heartbeat) who are also at high risk for stroke. It combines a procedure to fix the heart's electrical signals with closing off a small pouch in the heart to reduce stroke risk, potentially avoiding long-term blood thinners.

Bay Shore, New York
NCT07626411Recruiting· Phase 3
Blood Thinner Study for Irregular Heartbeat

This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.

Dothan, Alabama

Hear when a new Atrial Fibrillation (AF) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.